NGM Bio raises funds to launch clinical trial of aldafermin for PSC
NGM Biopharmaceuticals has raised $122 million in financing, which the California-based company will use to help launch a planned registrational clinical trial to test…
Cholangitis is a liver condition characterized by inflammation in the bile ducts, most commonly caused by a bacterial infection but also may develop due to a variety of other causes.
Read moreA variety of treatments may be used to treat cholangitis, depending on the type and whether it is acute or chronic.
Read moreNGM Biopharmaceuticals has raised $122 million in financing, which the California-based company will use to help launch a planned registrational clinical trial to test…
Six months of treatment with a high dose of bexotegrast, Pliant Therapeutics’ oral candidate, was superior to a placebo at reducing markers of disease…